{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:33:05Z","timestamp":1787016785972,"version":"build-2736575974"},"reference-count":29,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1134\/s1607672924700868","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T05:03:28Z","timestamp":1718082208000},"page":"166-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy"],"prefix":"10.1134","volume":"517","author":[{"given":"A. A.","family":"Godzenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Agafonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. E.","family":"Dimitreva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Yu.","family":"Razumova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Urumova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"137","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"7530_CR1","first-page":"cd011535","volume":"12","author":"E. Sbidian","year":"2017","unstructured":"Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., et al., Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis, Cochrane Database Syst. Rev., 2017, vol. 12, no. 12, p.\u00a0cd011535.","journal-title":"Cochrane Database Syst. Rev."},{"key":"7530_CR2","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W. Hueber","year":"2012","unstructured":"Hueber, W., Sands, B.E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., et al., Secukinumab in Crohn\u2019s Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial, Gut, 2012, vol. 61, no. 12, pp. 1693\u20131700. https:\/\/doi.org\/10.1136\/gutjnl-2011-301668","journal-title":"Gut"},{"key":"7530_CR3","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","volume":"111","author":"S.R. Targan","year":"2016","unstructured":"Targan, S.R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G.Y., Landers, C., Li, D., Russell, Ch., Newmark, R., Zhang, N., Chon, Yu., Hsu, Y.-H., Lin,\u00a0S.-L., and Klekotka, P., A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease, Am. J. Gastroenterol., 2016, vol. 111, no. 11, pp. 1599\u20131607. https:\/\/doi.org\/10.1038\/ajg.2016.298","journal-title":"Am. J. Gastroenterol."},{"key":"7530_CR4","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/art.21197","volume":"52","author":"J. Braun","year":"2005","unstructured":"Braun, J., Baraliakos, X., Listing, J., and Sieper, J., Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti\u2013tumor necrosis factor agents infliximab and etanercept, Arthritis Rheum., 2005, vol. 52, no. 8, pp. 2447\u20132451. https:\/\/doi.org\/10.1002\/art.21197","journal-title":"Arthritis Rheum."},{"key":"7530_CR5","doi-asserted-by":"publisher","first-page":"e000762","DOI":"10.1136\/rmdopen-2018-000762","volume":"4","author":"U. Lindstr\u00f6m","year":"2018","unstructured":"Lindstr\u00f6m, U., Olofsson, T., Wedr\u00e9n, S., Qirjazo, I., and Askling, J., Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study, RMD Open, 2018, vol. 4, no. 2, p. e000762. https:\/\/doi.org\/10.1136\/rmdopen-2018-000762","journal-title":"RMD Open"},{"key":"7530_CR6","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","volume":"76","author":"E. Lie","year":"2017","unstructured":"Lie, E., Lindstr\u00f6m, U., Zverkova-Sandstr\u00f6m, T., Olsen, I.C., Forsblad-D\u2019elia, H., Askling, J., Kapetanovic, M.C., Kristensen, L.E., and Jacobsson, L.T.H., Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register, Ann. Rheum. Dis., 2017, vol. 76, no. 9, pp. 1515\u20131521. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210931","journal-title":"Ann. Rheum. Dis."},{"key":"7530_CR7","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","volume":"30","author":"D. Wendling","year":"2014","unstructured":"Wendling, D., Joshi, A., Reilly, P., Jalundhwala, Ya.J., Mittal, M., and Bao, Ya., Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database, Curr. Med. Res. Opin., 2014, vol. 30, no. 12, pp. 2515\u20132521. https:\/\/doi.org\/10.1185\/03007995.2014.969368","journal-title":"Curr. Med. Res. Opin."},{"key":"7530_CR8","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/nejmoa1509852","volume":"375","author":"G.J. Jaffe","year":"2016","unstructured":"Jaffe, G.J., Dick, A.D., Br\u00e9zin, A.P., Nguyen, Q.D., Thorne, J.E., Kestelyn, P., Barisani-Asenbauer, T., Franco, P., Heiligenhaus, A., Scales, D., Chu, D.S., Camez, A., Kwatra, N.V., Song, A.P., Kron, M., Tari, S., and Suhler, E.B., Adalimumab in patients with active noninfectious uveitis, New Engl. J. Med., 2016, vol. 375, no. 10, pp. 932\u2013943. https:\/\/doi.org\/10.1056\/nejmoa1509852","journal-title":"New Engl. J. Med."},{"key":"7530_CR9","first-page":"1","volume":"9","author":"Sh. Koy","year":"2021","unstructured":"Koy, Sh., Labauge, E., Baillet, P., Prati, A., Marotte, C., Pers, H., and M, Y., Immunomodulation with IL-17 and TNF-\u03b1 in spondyloarthritis: focus on the eye and the central nervous system, Ther. Adv. Musculoskelet. Dis., 2021, vol. 9, no. 13, pp. 1\u201315.","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"7530_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/itt.s259126","volume":"10","author":"F. Atzeni","year":"2021","unstructured":"Atzeni, F., Carriero, A., Boccassini, L., and D\u2019angelo, S., Anti-IL-17 agents in the treatment of axial spondyloarthritis, Immuno Targets Ther., 2021, vol. 10, no. 10, pp.\u00a0141\u2013153. https:\/\/doi.org\/10.2147\/itt.s259126","journal-title":"Immuno Targets Ther."},{"key":"7530_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.14412\/1995-4484-2017-68-86","volume":"55","author":"E.L. Nasonov","year":"2017","unstructured":"Nasonov, E.L., New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: a focus on inhibitors of interleukin-17, Nauchno-Prakt. \n               Revmatol., 2017, vol. 55, no. 1, pp. 68\u201386. https:\/\/doi.org\/10.14412\/1995-4484-2017-68-86","journal-title":"Revmatol."},{"key":"7530_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.14412\/1995-4484-2017-201-210","volume":"55","author":"E.L. Nasonov","year":"2017","unstructured":"Nasonov, E.L., Mazurov, V.I., Usacheva, Yu.V., Chernyaeva, E.V., Ustyugov, Ya.Yu., Ulitin, A.B., and Ivanov, R.A., Developments of Russian original biological agents for the treatment of immunoinflammatory rheumatic diseases, Nauchno-Prakt. \n               Revmatol., 2017, vol. 55, no. 2, pp. 201\u2013210. https:\/\/doi.org\/10.14412\/1995-4484-2017-201-210","journal-title":"Revmatol."},{"key":"7530_CR13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.14412\/1995-4484-2019-400-406","volume":"57","author":"E.L. Nasonov","year":"2019","unstructured":"Nasonov, E.L., Korotaeva, T.V., Dubinina, T.V., and Lila, A.M., IL-23\/IL-17 inhibitors in immunoinflammatory rheumatic diseases: new horizons, Nauchno-Prakt. \n               Revmatol., 2019, vol. 57, no. 4, pp. 400\u2013406. https:\/\/doi.org\/10.14412\/1995-4484-2019-400-406","journal-title":"Revmatol."},{"key":"7530_CR14","first-page":"668","volume":"57","author":"S. Erdes","year":"2019","unstructured":"Erdes, S., Mazurov, V.I., Dubinina, T.V., Gaydukova, I.Z., Lapshina, S.A., et al., Efficacy and safety of a new original interleukin 17A inhibitor in the treatment of patients with active ankylosing spondylitis: results of a basic (BCD-085-3\/AILAS) and extended (BCD-085-3ext\/AILAS-II) phase II clinical trial, Nauchno-Prakt. \n               Revmatol., 2019, vol. 57, no. 6, pp. 668\u2013677.","journal-title":"Revmatol."},{"key":"7530_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.47360\/1995-4484-2020-646-657","volume":"58","author":"T.V. Dubinina","year":"2020","unstructured":"Dubinina, T.V., Gaydukova, I.Z., Sokolova, V.D., Mladov, V.V., and Tolkacheva, D.G., Efficacy and safety of biologics for the treatment of ankylosing spondylitis: systematic literature review and network meta-analysis of treatments registered in the Russian Federation, Nauchno-Prakt. \n               Revmatol., 2020, vol. 58, no. 6, pp. 646\u2013657. https:\/\/doi.org\/10.47360\/1995-4484-2020-646-657","journal-title":"Revmatol."},{"key":"7530_CR16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.47360\/1995-4484-2022-594-601","volume":"60","author":"T.V. Dubinina","year":"2022","unstructured":"Dubinina, T.V., Gaydukova, I.Z., Sableva, N.A., Sapozhnikov, K.V., Sokolova, V.D., and Tolkacheva, D.G., Comparative pharmacoeconomic effectiveness of interleukin-17 inhibitors for the treatment of ankylosing spondylitis, Nauchno-Prakt. \n               Revmatol., 2022, vol. 60, no. 6, pp. 594\u2013601. https:\/\/doi.org\/10.47360\/1995-4484-2022-594-601","journal-title":"Revmatol."},{"key":"7530_CR17","doi-asserted-by":"publisher","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","volume":"2","author":"W. Hueber","year":"2010","unstructured":"Hueber, W., Patel, D.D., Dryja, T., Wright, A.M., Koroleva, I., Bruin, G., Antoni, Ch., Draelos, Z., Gold, M.H., Durez, P., Tak, P.P., Gomez-Reino, J.J., Foster, C.S., Kim, R.Y., Samson, C.M., Falk, N.S., Chu, D.S., Callanan, D., Nguyen, Q.D., Rose, K., Haider, A., and Di Padova, F., Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis, Sci. Transl. Med., 2010, vol. 2, no. 52, p. 52ra72. https:\/\/doi.org\/10.1126\/scitranslmed.3001107","journal-title":"Sci. Transl. Med."},{"key":"7530_CR18","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","volume":"122","author":"E. Letko","year":"2015","unstructured":"Letko, E., Yeh, S., Foster, C.S., Pleyer, U., Brigell, M., and Grosskreutz, C.L., Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy, Ophthalmology, 2015, vol. 122, no. 5, pp. 939\u2013948. https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.033","journal-title":"Ophthalmology"},{"key":"7530_CR19","doi-asserted-by":"publisher","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","volume":"19","author":"J.M.G. Ruiz De Morales","year":"2020","unstructured":"Ruiz De Morales, J.M.G., Puig, L., Daud\u00e9n, E., Ca\u00f1ete, J.D., Pablos, J.L., Mart\u00edn, A.O., Juanatey, C.G., Ad\u00e1n, A., Montalb\u00e1n, X., Borruel, N., Ort\u00ed, G., Holgado-Mart\u00edn, E., Garc\u00eda-Vidal, C., Vizcaya-Morales, C., Mart\u00edn-V\u00e1zquez, V., and Gonz\u00e1lez-Gay, M.\u00c1., Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies, Autoimmun. Rev., 2020, vol. 19, no. 1, p. 102429. https:\/\/doi.org\/10.1016\/j.autrev.2019.102429","journal-title":"Autoimmun. Rev."},{"key":"7530_CR20","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J. Braun","year":"2017","unstructured":"Braun, J., Baraliakos, X., Deodhar, A., Baeten, D., Sieper, J., Emery, P., Readie, A., Martin, R., Mpofu, Sh., and Richards, H.B., Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study, Ann. Rheum. Dis., 2017, vol. 76, no. 6, pp. 1070\u20131077. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209730","journal-title":"Ann. Rheum. Dis."},{"key":"7530_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/acr2.11139","volume":"2","author":"A.A. Deodhar","year":"2020","unstructured":"Deodhar, A.A., Miceli-richard, C., Baraliakos, X., Marzo-ortega, H., Gladman, D.D., Blanco, R., Das Gupta, A., Martin, R., Safi, J., Porter, B., Shete, A., and Rosenbaum, J.T., Incidence of uveitis in secukinumab-treated patients with ankylosing spondylitis: pooled data analysis from three phase 3 studies, ACR Open Rheumatol., 2020, vol. 2, no. 5, pp. 294\u2013299. https:\/\/doi.org\/10.1002\/acr2.11139","journal-title":"ACR Open Rheumatol."},{"key":"7530_CR22","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/annrheumdis-2021-220420","volume":"80","author":"U. Lindstr\u00f6m","year":"2021","unstructured":"Lindstr\u00f6m, U., Bengtsson, K., Olofsson, T., Di Giuseppe, D., Glintborg, B., Forsblad-D\u2019elia, H., Jacobsson, L.T.H., and Askling, J., Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?, Ann. Rheum. Dis., 2021, vol. 80, no. 11, pp. 1445\u20131452. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220420","journal-title":"Ann. Rheum. Dis."},{"key":"7530_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S. Ramiro","year":"2023","unstructured":"Ramiro, S., Nikiphorou, E., Sepriano, A., Ortolan, A., Webers, C., et al., ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update, Ann. Rheum. Dis., 2023, vol. 82, no. 1, pp. 19\u201334.","journal-title":"Ann. Rheum. Dis."},{"key":"7530_CR24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","volume":"125","author":"A.D. Dick","year":"2018","unstructured":"Dick, A.D., Rosenbaum, J.T., Ha, A.-D., Jr, B.R., and Br\u00e9zinap, Fundamentals of Care for Uveitis International Consensus Group. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative, Ophthalmology, 2018, vol. 125, no.\u00a05, pp. 757\u2013773.","journal-title":"Ophthalmology"},{"key":"7530_CR25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","volume":"120","author":"A.D. Dick","year":"2013","unstructured":"Dick, A.D., Tugal-Tutkun, I., Foster, S., Zierhut, M., Melissa Liew, S.H., Bezlyak, V., and Androudi, S., Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials, Ophthalmology, 2013, vol. 120, no. 4, pp. 777\u2013787. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.040","journal-title":"Ophthalmology"},{"key":"7530_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S. Van Der Linden","year":"1984","unstructured":"Van Der Linden, S., Valkenburg, H.A., and Cats, A., Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria, Arthritis Rheum., 1984, vol. 27, no. 4, pp. 361\u2013368.","journal-title":"Arthritis Rheum."},{"key":"7530_CR27","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3899\/jrheum.131289","volume":"41","author":"J.Ch. Van Denderen","year":"2014","unstructured":"Van Denderen, J.Ch., Visman, I.M., Nurmoha-med,\u00a0M.T., Suttorp-Schulten, M.S.A., and Van Der Horst-Bruinsma, I.E., Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis, J. Rheumatol., 2014, vol.\u00a041, no. 9, pp. 1843\u20131848. https:\/\/doi.org\/10.3899\/jrheum.131289","journal-title":"J. Rheumatol."},{"key":"7530_CR28","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/ard.2008.092585","volume":"68","author":"M. Rudwaleit","year":"2009","unstructured":"Rudwaleit, M., R\u00f8devand, E., Holck, P., Vanhoof, J., Kron, M., Kary, S., and Kupper, H., Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study, Ann. Rheum. Dis., 2009, vol. 68, no. 5, pp. 696\u2013701. https:\/\/doi.org\/10.1136\/ard.2008.092585","journal-title":"Ann. Rheum. Dis."},{"key":"7530_CR29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/imcrj.s265812","volume":"13","author":"H. Nadwi","year":"2020","unstructured":"Nadwi, H., Janaini, M., Zammo, M., Cheikh, M., and Almoallim, H., New-onset uveitis possibly caused by secukinumab in a 47-year-old male patient with long-standing ankylosing spondylitis, Int. Med. Case Rep. J., 2020, vol. 13, pp. 331\u2013334. https:\/\/doi.org\/10.2147\/imcrj.s265812","journal-title":"Int. Med. Case Rep. J."}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672924700868.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1607672924700868","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672924700868.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:17:56Z","timestamp":1773760676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1607672924700868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7530"],"URL":"https:\/\/doi.org\/10.1134\/s1607672924700868","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors of this work declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONFLICT OF INTEREST"}},{"value":"The study was carried out within the framework of scientific topic no. 1021051503111-9 \u201cImproving the Diagnosis and Pharmacotherapy of Spondyloarthritis Based on Comparative Results of Studying Prognostic (Including Molecular Biological, Molecular Genetic, and Clinical Imaging) Factors of Disease Progression and the Level of Quality of Life of Patients,\u201d approved by the Academic Council of the Nasonova Research Institute of Rheumatology. The study was approved by the Local Ethics Committee of the Nasonova Research Institute of Rheumatology (protocol no. 02 dated January 27, 2022). All study participants signed voluntary informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}}]}}